Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrate 200 mg on HDL-C in comparison to the combination of simvastatin 20 mg and ezetimibe 10 mg in patients with metabolic syndrome
To confirm that the combination of fluvastatin 80 mg extended release (ER) and fenofibrate 200 mg has superior efficacy in increasing HDL-C compared with the combination of simvastatin 20 mg and ezeti...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo and oral corticosteroid in healthy volunteers
• To assess the ability of AIN457 to inhibit ozone-induced airway neutrophilia (total neutrophil cell count in 106/mL) in induced sputum at 24 hours compared to placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
CAUY922A2202 : Essai de phase 2 randomisé comparant l’efficacité de l’AUY922 à une chimiothérapie par docétaxel ou irinotécan, chez des patients ayant un cancer gastrique avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité de l’AUY922, à une chimiothérapie par docétaxel ou irinotécan, chez des patients ayant un cancer gastrique avancé. Les patients seront répartis de...
Country
France
organs
Estomac
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
Étude NATALEE : étude de phase 3, randomisée, évaluant l'efficacité et la tolérance du ribociclib associé à un traitement endocrine, comme traitement adjuvant, chez des patients ayant un cancer du sein HR+/HER2-.
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-ne...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis
Update Il y a 4 ans
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 6 ans
Étude GEP-NEC : étude de phase 2 visant à évaluer l’efficacité et la sécurité d’emploi du PDR001 chez des patients ayant des tumeurs neuroendocrines non-fonctionnelles avancées ou métastatiques bien différentiées du pancréas, du tractus gastrointestinal ou du thorax ou un carcinome neuroendocrine gastroenteropancréatique peu différentié qui a progressé sous un traitement antérieur.
Les tumeurs neuroendocrines prennent naissance dans les cellules du système neuroendocrinien qui sont dispersées dans tout le corps. Ces cellules reçoivent des signaux du système nerveux et fabriquent...
Country
France
organs
Système endocrinien - autres
,
Pancréas
,
Estomac
,
Intestin
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
To evaluate the bioavailability of: 5 x 1 mg everolimus intact tables, and 5 x 1 mg everolimus tablets suspended in 30 mL of water
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Phase II study for the treatment of abdominal aortic aneurysm
To assess the effect of ACZ885 on AAA size and growth rate as measured with ultrasound at 12 months.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
NOVARTIS CAMN107G2301 : Essai de phase 3 randomisé comparant l’efficacité et la tolérance du nilotinib à celle de l’imatinib, chez des patients ayant une tumeur stromale gastro-intestinale non opérable ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized, open label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumor...
Country
France
organs
Tumeurs stromales digestives (GIST)
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression
To evaluate the safety and tolerability profile of the combination therapy of an antidepressant type SSRI or SNRI with oral fingolimod with respect to adverse events and laboratory parameters
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next